Becton Dickinson (BDX) announced full enrollment of the iliac artery patient cohort in its AGILITY investigational device exemption study, a prospective, multi-center study evaluating the Revello vascular covered stent in patients with peripheral arterial disease.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- BDX Upcoming Earnings Report: What to Expect?
- Becton Dickinson receives FDA clearance, CE mark for enteric bacterial panels
- BD’s New Vascular Access Study: What Investors Need to Know
- BDX’s SiteRite 9 Study: A New Frontier in Ultrasound-Guided Vascular Access
- Becton, Dickinson’s New Study on Sepsis Diagnostic Vials: Market Implications